KRAS and pancreatic neoplasm: The panel tested for the presence cfDNA KRAS mutations and serum levels of CA19-9, CEA, HGF and OPN—protein markers that are used clinically to follow pancreatic cancer patient treatment course or have been previously found to be dysregulated in pancreatic cancer patients.